Interview with Jim Breyer #venturecapital - Codice 11/07/2025
L'intervista in lingua originale a Jim Breyer, Venture Capitalist che tra i primi nel mondo investì in Facebook, moltiplicando per 100 ...
Early investor in Facebook, Breyer Capital
Search every verified Jim Breyer interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jim Breyer, founder and CEO of Breyer Capital, has been active in discussions about artificial intelligence, healthcare, and technology investing. In a July 2025 interview, he stated that AI is "fundamental to almost everything that we'll see and do" and described having made about 15 investments in AI and health, spanning diagnosis, preventive care, and drug discovery. He said his approach involves identifying Nobel laureates or potential Nobel laureates in medicine and pairing them with AI talent from companies like Google, Meta, and Microsoft. Breyer also commented on the Stargate Project, a $500 billion AI infrastructure initiative, calling it "too big, too expensive" and giving it a 9.5 out of 10 on a difficulty scale, while noting that capital expenditure projects of that scale "tend to not work." Breyer has also discussed his investment in Circle, the stablecoin company, which went public in 2025. He said he invested in 2013 after meeting with co-founders Jeremy Allaire and Sean Neville, describing his cost basis as $0.27 per share. He noted that regulatory challenges were always a risk but that Allaire had "a sense of wanting to be regulated in the right way." Regarding Meta, Breyer said in early 2025 that he sees a "revitalized Mark Zuckerberg" and that the company is "as well positioned in AI as anyone out there." He has also expressed optimism about Nvidia and AMD, stating that Nvidia is "unstoppable" over a three-year timeframe and that he would add AMD to the list of "Magnificent Seven" stocks.
“AI is fundamental to almost everything that we'll see and do. It affects finance, transportation, but perhaps most importantly, it has profound and very positive potential to make a big difference for patients, for doctors, for drug discovery.”
“One of the great promises of what Chuck Fraser and his team are doing is you can capture the data and suddenly enable those kinds of surgeries to occur in other parts of the United States and other parts of the world.”
“I think psychedelics is largely a bubble. The research is early and the preference of Breyer Capital has been to invest in many other areas where medicine and AI intersect.”
“As a venture capitalist and investor I always worry, but now more than ever. But what I will also say with AI, I'm an optimist. I'm very optimistic about how AI will have a profound positive influence on venture capitalists and investors who think out of the box.”
“I invested $11 million in Facebook in 2005 and joined the board because Mark Zuckerberg had deep product passion and a vision to connect three billion or more people.”
“The biggest mistake I rarely make is the mistake of the wrong entrepreneur and I rarely make the mistake of investing in something where there is not a market eventually. The challenge is putting it all together: the market, the timing, regulatory risk.”
“Europe has superb intellectual talent and universities, but regulatory issues have held back startups. Overregulation of AI would be a huge mistake because we don't yet know enough about AI to do detailed regulation.”
“Digital sovereignty matters in the race for AI breakthroughs. Important AI research is coming from the US, China, and Europe. The key is to accelerate commercialization and scaling, especially in Europe.”
“I care deeply about the impact and whether it has a positive social impact. At Facebook, we didn't fully understand privacy and security issues early on, and we underinvested in those areas.”
“The most important set of skills today is interdisciplinary. Teams need medical expertise, biology, chemistry, and computer science to succeed in AI and medicine.”
“Elon, a genius. I'm an investor in several of the Elon companies. He hires extraordinarily well, and we don't often hear enough about people like Omead Afshar and others who are on his senior team in terms of what's going on at the president level.”
“I'm always nervous.”
“I think there's a great deal at stake. But I'm also very optimistic around the products that they're delivering, usually late. That's okay.”
“These are breathtakingly good technologists at Tesla and SpaceX.”
“In 2013 Jeremy and Sean called me and said, we have an idea about the future of money. After two hours, I shook hands with both of them and said, I'm in.”
L'intervista in lingua originale a Jim Breyer, Venture Capitalist che tra i primi nel mondo investì in Facebook, moltiplicando per 100 ...
Jim Breyer, Breyer Capital founder and CEO, joins 'Money Movers' to discuss investing in Circle, which made its public debut ...
Jim Breyer, Breyer Capital founder and CEO, joins 'Money Movers' to discuss investing in Circle, which made its public debut ...
Jim Breyer: "Be passionate. Love what you do. There's never the right background or pedigree that matters." Here are a few ...
How are AI and quantum technologies reshaping healthcare and deep tech investment? At this year's World Economic Forum ...
Jim Breyer, Breyer Capital founder and CEO, shares his thoughts on Mark Zuckerberg and how Facebook is positioned in the AI race.
Jim Breyer, Breyer Capital founder and CEO, joins 'Money Movers' to discuss the 'Stargate Project' investment in AI infrastructure, ...
Could AI be the key to unlocking breakthrough treatments for Alzheimer’s? In this CNBC Money Movers segment, SandboxAQ CEO Jack Hidary and investor Jim Breyer discuss how advanced AI is transforming healthcare, dramatically reducing drug discovery timelines for diseases like Alzheimer’s, cancer, Parkinson’s, and more. In honor of World Alzheimer’s Month, Jack explains how SandboxAQ is leveraging Large Quantitative Models (LQMs) and partnering with NVIDIA and UCSF to identify critical compounds for neurodegenerative diseases in under 18 months—compared to the typical 10-year development cycle.…
President Jay Hartzell leads a discussion with Jim Breyer, founder/CEO, Breyer Capital; Thomas J. Cahill III, M.D., Ph.D., founder ...
Breyer Capital founder and CEO Jim Breyer joins 'Squawk Box' to discuss the impact of AI on the VC landscape, how AI can change health care, and more.
Sign in to search the full transcript archive, filter by topic, and access every quote from Jim Breyer.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →